Literature DB >> 32190415

Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants.

Christopher G Tarolli1, Grace A Zimmerman1, Steven Goldenthal1, Blake Feldman1, Sarah Berk1, Bernadette Siddiqi1, Catherine M Kopil1, Sohini Chowdhury1, Kevin M Biglan1, E Ray Dorsey1, Jamie L Adams1.   

Abstract

BACKGROUND: Use of video research visits in neurologic conditions is rising, but their utility has not been assessed in atypical parkinsonian syndromes. We sought to evaluate the diagnostic concordance between video-based vs self-reported diagnoses of multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and corticobasal syndrome. We also assessed patient satisfaction with video-based visits.
METHODS: We conducted a study of video-based research visits in individuals with an atypical parkinsonian syndrome enrolled in The Michael J. Fox Foundation's Fox Trial Finder. Participants completed a recorded real-time video visit with a remote evaluator who was blinded to the participant's self-reported diagnosis. The investigator conducted a structured interview and performed standard assessments of motor function. Following the visit, the investigator selected the most likely diagnosis. The recorded visit was reviewed by a second blinded investigator who also selected the most likely diagnosis. We evaluated diagnostic concordance between the 2 independent investigators and assessed concordance between investigator consensus diagnosis and self-reported diagnosis using Cohen's kappa. We assessed participant satisfaction with a survey.
RESULTS: We enrolled 45 individuals with atypical parkinsonian syndromes, and 44 completed the investigator-performed video assessment. We demonstrated excellent concordance in diagnosis between the investigators (κ = 0.83) and good reliability of self-reported diagnosis (κ = 0.73). More than 90% of participants were satisfied or very satisfied with the convenience, comfort, and overall visit.
CONCLUSIONS: Video research visits are feasible and reliable in those with an atypical parkinsonian syndrome. These visits represent a promising option for reducing burden and extending the reach of clinical research to individuals with these rare and disabling conditions.
© 2019 American Academy of Neurology.

Entities:  

Year:  2020        PMID: 32190415      PMCID: PMC7057071          DOI: 10.1212/CPJ.0000000000000680

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  14 in total

1.  Quantitative telemedicine ratings in Batten disease: implications for rare disease research.

Authors:  J Cialone; E F Augustine; N Newhouse; A Vierhile; F J Marshall; J W Mink
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

2.  Home-Based Trials in Adolescent Migraine: A Randomized Clinical Trial.

Authors:  Amy A Gelfand; William Qubty; Irene Patniyot; Barbara Grimes; Mark J Pletcher; Peter J Goadsby; Steven R Cummings
Journal:  JAMA Neurol       Date:  2017-06-01       Impact factor: 18.302

3.  A pilot study of virtual visits in Huntington disease.

Authors:  Michael T Bull; Kristin Darwin; Vinayak Venkataraman; Joseph Wagner; Christopher A Beck; E Ray Dorsey; Kevin M Biglan
Journal:  J Huntingtons Dis       Date:  2014

4.  ALSUntangled No. 26: lunasin.

Authors: 
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-09-23       Impact factor: 4.092

5.  Enrollment of research subjects through telemedicine networks in a multicenter acute intracerebral hemorrhage clinical trial: design and methods.

Authors:  J Alfredo Caceres; David M Greer; Joshua N Goldstein; Anand Viswanathan; Jose I Suarez; Logan Brau; Joseph Christopher Zacko; Theodore J Lowenkopf; Chad M Miller; Qaisar A Shah; Ira Chang; Souvik Sen; Steven R Messe; Sherry H Chou; Adnan I Qureshi
Journal:  J Vasc Interv Neurol       Date:  2014-09

Review 6.  Novel methods and technologies for 21st-century clinical trials: a review.

Authors:  E Ray Dorsey; Charles Venuto; Vinayak Venkataraman; Denzil A Harris; Karl Kieburtz
Journal:  JAMA Neurol       Date:  2015-05       Impact factor: 18.302

Review 7.  Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

8.  A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study.

Authors:  Caroline M Tanner; Cheryl C Meng; Bernard Ravina; Anthony Lang; Roger Kurlan; Kenneth Marek; David Oakes; John Seibyl; Emily Flagg; Lisa Gauger; Dolores D Guest; Christopher G Goetz; Karl Kieburtz; Diane DiEuliis; Stanley Fahn; Robin A Elliott; Ira Shoulson
Journal:  Mov Disord       Date:  2014-02-11       Impact factor: 10.338

9.  Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

Authors:  Adam L Boxer; Anthony E Lang; Murray Grossman; David S Knopman; Bruce L Miller; Lon S Schneider; Rachelle S Doody; Andrew Lees; Lawrence I Golbe; David R Williams; Jean-Cristophe Corvol; Albert Ludolph; David Burn; Stefan Lorenzl; Irene Litvan; Erik D Roberson; Günter U Höglinger; Mary Koestler; Clifford R Jack; Viviana Van Deerlin; Christopher Randolph; Iryna V Lobach; Hilary W Heuer; Illana Gozes; Lesley Parker; Steve Whitaker; Joe Hirman; Alistair J Stewart; Michael Gold; Bruce H Morimoto
Journal:  Lancet Neurol       Date:  2014-05-27       Impact factor: 44.182

10.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

View more
  8 in total

1.  Patients' Postjudice of Tele-Neurology for Movement Disorders.

Authors:  Ishani Rajapakshe; Elisa Menozzi; Inês Cunha; Andrew J Lees; Kailash P Bhatia; Eoin Mulroy
Journal:  Mov Disord Clin Pract       Date:  2022-04-01

2.  Practicing in a Pandemic: A Clinician's Guide to Remote Neurologic Care.

Authors:  Christopher G Tarolli; Julia M Biernot; Peter D Creigh; Emile Moukheiber; Rachel Marie E Salas; E Ray Dorsey; Adam B Cohen
Journal:  Neurol Clin Pract       Date:  2021-04

3.  Telemedicine: A valuable tool in neurodegenerative diseases.

Authors:  Jamie L Adams; Taylor L Myers; Emma M Waddell; Kelsey L Spear; Ruth B Schneider
Journal:  Curr Geriatr Rep       Date:  2020-03-14

Review 4.  The state of telemedicine for persons with Parkinson's disease.

Authors:  Robin van den Bergh; Bastiaan R Bloem; Marjan J Meinders; Luc J W Evers
Journal:  Curr Opin Neurol       Date:  2021-08-01       Impact factor: 6.283

5.  A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease: Baseline Results.

Authors:  Stella Jensen-Roberts; Taylor L Myers; Peggy Auinger; Paul Cannon; Helen M Rowbotham; Daniella Coker; Eli Chanoff; Julia Soto; Meghan Pawlik; Katherine Amodeo; Saloni Sharma; Blanca Valdovinos; Renee Wilson; Aayush Sarkar; Michael P McDermott; Roy N Alcalay; Kevin Biglan; Daniel Kinel; Caroline Tanner; Reni Winter-Evans; Erika F Augustine; Robert G Holloway; E Ray Dorsey; Ruth B Schneider
Journal:  Neurol Genet       Date:  2022-08-11

6.  A systematic review of methods used to conduct decentralised clinical trials.

Authors:  Amy Rogers; Giorgia De Paoli; Selvarani Subbarayan; Rachel Copland; Kate Harwood; Joanne Coyle; Lyn Mitchell; Thomas M MacDonald; Isla S Mackenzie
Journal:  Br J Clin Pharmacol       Date:  2022-01-27       Impact factor: 3.716

7.  Konzo outbreak in Zambia linked to cassava-based diet.

Authors:  Heather Wood
Journal:  Nat Rev Neurol       Date:  2020-05       Impact factor: 42.937

Review 8.  Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.

Authors:  Jennifer G Goldman; Leah K Forsberg; Bradley F Boeve; Melissa J Armstrong; David J Irwin; Tanis J Ferman; Doug Galasko; James E Galvin; Daniel Kaufer; James Leverenz; Carol F Lippa; Karen Marder; Victor Abler; Kevin Biglan; Michael Irizarry; Bill Keller; Leanne Munsie; Masaki Nakagawa; Angela Taylor; Todd Graham
Journal:  Alzheimers Res Ther       Date:  2020-10-29       Impact factor: 6.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.